Cellular Rejuvenation Factors for ROS Reduction and Tissue Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current skin rejuvenation methods, such as surgical interventions and minimally invasive treatments, are invasive, inconvenient, and do not address the underlying aging phenotype on a molecular or cellular level, lacking effective screening and target verification for cellular rejuvenation.
Innovation Solution
The use of specific proteins or nucleic acids, including ANXA2, PRRC2B, MAP4, BGN, CLTA, RPS23, AKT1, VCP, FAM129B, LMAN1, GUK1, SEC61A1, ELL2, RPN1, KIF5B, MSN, TGOLN2, EIF4H, RPLP1, ASPH, SERBP1, NACA, SIPA1L1, ITGA5, BTF3, CAP1, MYDGF, YBX1, MRC2, ITGB1, EEF1B2, GAPDH, EIF4G2, S100A11, PFN1, MAGED1, CTNNA1, RPL12, FKBP10, FLII, TAGLN2, ENO1, SURF4, RSRC2, CLIC1, DAG1, LGALS1, GSR, RPL29, PRDX1, UBB, CAPN2, MVP, SEPT10, SEPT8, TLN1, RPL23A, GNAS, IPO5, RPS8, PABPC1, ARF1, RPL10A, U2AF2, ACTN4, RPS24, ARPC5, FTL, MAGED2, RPL37, RPSA, VDAC1, ANXA6, RPS3A, HP1BP3, THRAP3, RPL32, TMSB4X, HSPA8, GNAI2, SPATS2L, PDIA4, RPS7, MYL12B, CCT3, TPI1, S100A4, S100A6, SND1, DDX1, RPL35A, SH3BGRL3, RPL23, TPM3, TMED10, EEF1A1, GNB1, EIF4G1, EIF1, RPLP0, EIF5A, XRCC6, RPS3, VIM, COPB1, RPS19, and HSPA9, to induce cellular rejuvenation and regeneration by reducing ROS and increasing growth rate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical interventions are used for skin rejuvenation, then the appearance of aging is reduced, but the procedure is invasive, inconvenient, and expensive
Solution Approach 1:
The patent replaces mechanical/surgical interventions with molecular and cellular mechanisms. By introducing rejuvenation factors (proteins, nucleic acids, or cells) that act at the molecular level to reverse aging phenotypes, the invention eliminates the need for invasive surgical procedures while achieving similar or superior rejuvenation effects.
Solution Approach 2:
The patent changes the fundamental parameters of treatment by shifting from macroscopic surgical modifications to microscopic molecular and cellular interventions. The treatment parameters are defined by the introduction of specific rejuvenation factors that modify cellular behavior, gene expression, and protein function, thereby achieving rejuvenation without physical invasiveness.
2Ease of operation
If minimally invasive methods are used, then convenience is improved, but effectiveness is reduced compared to surgical interventions
Solution Approach 1:
The patent replaces conventional minimally invasive mechanical methods (such as lasers, radiofrequency, ultrasound) with biological mechanisms. By using rejuvenation factors that directly modify cellular and molecular processes, the invention achieves superior effectiveness compared to energy-based methods while maintaining minimal invasiveness.
Solution Approach 2:
The patent introduces rejuvenation factors (proteins, nucleic acids, or cells) as intermediary substances that mediate the rejuvenation process. These intermediaries act within the cell to reverse aging phenotypes, providing a more effective mechanism than direct energy application while requiring only minimal tissue penetration for delivery.
3Shape
If energy-based methods are used to improve skin texture, then skin appearance is improved, but longer patient healing times are required
Solution Approach 1:
The patent replaces energy-based physical treatment with molecular and cellular mechanisms. By introducing rejuvenation factors that directly modify cellular function and gene expression, the invention achieves skin texture improvement without the thermal or mechanical damage that requires extended healing periods.
Solution Approach 2:
The patent performs rejuvenation actions at the molecular and cellular level before structural changes are needed. By pre-modifying gene expression, protein function, and cellular metabolism through rejuvenation factors, the skin structure and texture improve as a result of these underlying molecular changes, eliminating the need for prolonged healing.
4Measurement precision
If hypothesis-driven screening methods are used, then target verification is achieved, but throughput is limited
Solution Approach 1:
The patent employs a universal screening platform that can simultaneously evaluate multiple rejuvenation candidates using the same assay system. The phenotypic screening method uses universal readouts (such as cellular age markers, functional assays, or imaging) that can assess multiple proteins, nucleic acids, or cell-based rejuvenation factors in parallel, dramatically increasing throughput while maintaining verification accuracy.
Solution Approach 2:
The patent uses computational models and in silico simulations to create virtual copies of cellular aging processes. These digital models allow rapid virtual screening and verification of rejuvenation targets before physical experimentation, enabling high-throughput identification of promising candidates while maintaining scientific rigor through validated computational algorithms.
Data Source
AI summary
The present disclosure relates to a method of inducing cellular rejuvenation and/or regeneration of a cell or tissue comprising contacting the cell with an effective amount of a protein or nucleic acid encoding a protein that induces cellular rejuvenation and/or regeneration of a cell or tissue. The present disclosure describes cell or tissue prepared according to methods described herein. The present disclosure also provides for methods of treating patients using cell or tissue generated by the methods described herein. The present disclosure also provides methods and systems for identifying a perturbant capable of changing a cell's state, function, and predicted age from an old reference state to a younger altered state.